Vascugen
Vascugen is a pre-clinical biotechnology company developing iPSC-derived vasculogenic cell therapies that form new microvascular blood vessels to treat ischemic vascular diseases such as Critical Limb Ischemia and Diabetic Retinopathy.
- Company typePrivate
- Founded2018
- HeadquartersMadison, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
Vascugen firmographics
Firmographics- Name
- Vascugen
- Legal name
- Vascugen Inc.
- Website
- https://vascugen.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Vascugen is a pre-clinical biotechnology company developing iPSC-derived vasculogenic cell therapies that form new microvascular blood vessels to treat ischemic vascular diseases such as Critical Limb Ischemia and Diabetic Retinopathy.
- Ownership category
- akta.pro rank
Vascugen industry classification
Industry- Product category
- Regenerative Medicine Cell Therapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis) (HLAAAGAJ)
- akta.pro secondary industries
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Vascular Medicine (Peripheral Arterial/Venous Disease) (HLAKABAG)
Keywords
Where Vascugen is headquartered
LocationHeadquarters
- HQ city
- Madison
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Vascugen business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Supply Chain, Others
Revenue model
- Regenerative Medicine Products: Pre-revenue biotech company developing iPSC-derived cell therapy products for vascular degenerative conditions. Revenue will be generated through commercialization of therapeutic candidates following regulatory approval. Target conditions include Critical Limb Ischemia and Diabetic Retinopathy.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Vascugen product offering
Product offeringCore offering
Vascugen is a pre-clinical biotechnology company developing iPSC-derived vasculogenic cell therapies designed to directly form new blood vessels (vasculogenesis) and restore microvascular circulation in oxygen-starved tissues. Its lead candidates target Critical Limb Ischemia (CLI) and Diabetic Retinopathy (DR), conditions with limited or no effective treatments. The company is building a full-stack iPSC therapeutics platform spanning cell differentiation, gene modification, manufacturing, and clinical delivery.
Product overview
Vascugen is a regenerative medicine company developing iPSC-derived vasculogenic cells as a cell replacement therapy to restore microvascular circulation in patients with ischemic conditions. The company's 'Full Stack' iPSC Therapeutics Platform integrates all stages of development from iPSC原材料 through to clinical manufacturing, including proprietary cell differentiation technology, critical quality attribute assays, CRISPR/CAS9 gene modification capabilities, and specialized delivery systems. The lead product candidate is an allogeneic, donor-independent vasculogenic cell therapy designed to directly form new blood vessels in oxygen-starved tissues.
Differentiator
Problem solved
Functional benefit
Products and services
- iPSC-Derived Vasculogenic Cell Therapy
Companies that use Vascugen
Customer profileSegments2 records
Ideal customer profiles2 records
Vascugen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Vascugen partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core and supporting.
- Indiana UniversitycoreVascugen launched in 2018 in partnership with Indiana University (IU), a leading institution for medical research. Vascugen has exclusive rights from IU to a broad technology portfolio developed in the laboratory of scientific founder Dr. Mervin C. Yoder. The partnership involves licensing of stem cell technology for blood vessel regeneration developed at IU School of Medicine.
- Cook RegentecsupportingVascugen utilizes ProFusion Therapeutic Infusion Needle and Compass CT technologies from Cook Regentec for efficient intramuscular cell delivery. This partnership provides the delivery mechanism for their iPSC-derived vasculogenic cell therapy products.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
Vascugen competitors and assessment
Company assessmentBroad incumbents
- Vericel: Commercial-stage cell therapy company with marketed autologous cell therapy products. Comparable to Vascugen in the cell therapy commercialization model, providing a benchmark for what allogeneic vascular cell therapy commercialization could look like.
- BlueRock Therapeutics: Bayer-owned clinical-stage cell therapy company developing iPSC-derived cell therapies, focused primarily on neurology and cardiology. Comparable to Vascugen as an iPSC platform developer, though BlueRock is much better capitalized and at later development stage.
- Sana Biotechnology: Clinical-stage cell therapy company developing iPSC-derived allogeneic cell therapies with significant capital backing. Comparable to Vascugen in the iPSC platform and allogeneic cell therapy approach, though at substantially larger scale and broader scope.
Emerging players
- ViaCyte: Clinical-stage regenerative medicine company developing stem cell-derived therapies (originally acquired by Vertex). Comparable to Vascugen as a stem cell-derived therapy developer, though focused on diabetes (encapsulated pancreatic cells) rather than vascular indications.
Others
- Cook Medical (Cook Regentec): Medical device company providing cell and gene therapy delivery technologies including the ProFusion needle used by Vascugen. Listed as a technology/integration partner rather than competitor; relevant as the delivery mechanism supplier and an adjacent participant in the regenerative medicine ecosystem.
Direct peers
- Cynata Therapeutics: Clinical-stage company developing iPSC-derived mesenchymal stem cell (MSC) therapies for inflammatory and vascular conditions. Highly comparable to Vascugen as an iPSC platform company targeting similar indications using stem cell-derived therapies.
- Caladrius Biosciences: Clinical-stage cell therapy company with programs targeting ischemic conditions including CLI and other vascular diseases using autologous cell therapy. Comparable to Vascugen in the CLI-targeted cell therapy space, with overlapping target indications.
- Humacyte: Clinical-stage regenerative medicine company developing bioengineered human blood vessels and tissue products. Highly comparable to Vascugen in the vascular regeneration space, though Humacyte focuses on tissue-engineered vessel scaffolds rather than iPSC-derived vasculogenic cell therapy.
- Pluristem Therapeutics: Cell therapy company developing placenta-derived allogeneic cell products for multiple ischemic and inflammatory conditions including peripheral artery disease. Directly comparable to Vascugen in the allogeneic cell therapy approach to vascular disease.
- Athersys: Clinical-stage cell therapy company developing MultiStem, an allogeneic stem cell platform, with programs in vascular and inflammatory conditions. Comparable to Vascugen as a developer of allogeneic, off-the-shelf cell therapies targeting ischemic disease.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
Vascugen social profiles
Digital presenceVascugen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vascugen leadership team
Management profileNumber of profiles
Profiles4 records
Vascugen funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vascugen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vascugen
What does Vascugen do?
Vascugen is a pre-clinical biotechnology company developing iPSC-derived vasculogenic cell therapies designed to directly form new blood vessels (vasculogenesis) and restore microvascular circulation in oxygen-starved tissues. Its lead candidates target Critical Limb Ischemia (CLI) and Diabetic Retinopathy (DR), conditions with limited or no effective treatments. The company is building a full-stack iPSC therapeutics platform spanning cell differentiation, gene modification, manufacturing, and clinical delivery.
Is Vascugen a public or private company?
Vascugen is a private company. It is classified as venture growth investor backed and is currently operating.
When was Vascugen founded?
Vascugen was founded in 2018. It employs 11 to 50 people.
Where is Vascugen based?
Vascugen is headquartered in Madison, United States, in the North America region.
How does Vascugen make money?
One revenue line is on record: regenerative Medicine Products.
Who are Vascugen's main competitors?
Broad incumbents on record are Vericel, BlueRock Therapeutics and Sana Biotechnology. ViaCyte is listed as an emerging player. Cook Medical (Cook Regentec) is listed as an others. Direct peers are Cynata Therapeutics, Caladrius Biosciences, Humacyte, Pluristem Therapeutics and Athersys.
Does Vascugen have an API?
No public API is recorded for Vascugen.
What industry is Vascugen in?
Vascugen's product category is Regenerative Medicine Cell Therapy. Its primary akta.pro industry code is HLAAAGAJ, Cardiovascular & Vascular Regeneration (vascular grafts, angiogenesis), with a secondary code of HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals. Its NAICS code is 541714 and its SIC code is 8731.